Efficacy and safety of crizotinib in patients with advanced <i>c-MET</i>-amplified non-small cell lung cancer (NSCLC).

American Society of Clinical Oncology (ASCO) - Tập 32 Số 15_suppl - Trang 8001-8001 - 2014
D. Ross Camidge1, Sai‐Hong Ignatius Ou2, Geoffrey I. Shapiro3, Gregory A. Otterson4, Liza C. Villaruz5, Miguel A. Villalona‐Calero6, A. John Iafrate7, Marileila Varella‐Garcia8, Sanja Đačić9, Stephanie Cardarella3, Weiqiang Zhao6, L. Tye10, Patricia Stephenson11, Keith D. Wilner10, Leonard P. James10, Mark A. Socinski12
1University of Colorado Cancer Center, Aurora, CO
2Chao Family Comprehensive Cancer Center, Orange, CA
3Dana-Farber Cancer Institute, Boston, MA
4Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH;
5University of Pittsburgh Cancer Institute, Pittsburgh, PA
6Ohio State University Wexner Medical Center, Columbus, OH
7Massachusetts General Hospital, Boston, MA
8University of Colorado School of Medicine, Aurora, CO
9University of Pittsburgh Medical Center, Pittsburgh, PA
10Pfizer Oncology, La Jolla, CA
11Rho Inc, Chapel Hill, NC
12University of Pittsburgh, Pittsburgh, PA

Tóm tắt

Từ khóa


Tài liệu tham khảo

Thông tin
Thông tin xuất bản

American Society of Clinical Oncology (ASCO)

Tập 32 Số 15_suppl

8001-8001

Thông tin tác giả